4//SEC Filing
Kerr Douglas 4
Accession 0000950170-25-097006
CIK 0001818794other
Filed
Jul 17, 8:00 PM ET
Accepted
Jul 18, 5:20 PM ET
Size
6.1 KB
Accession
0000950170-25-097006
Insider Transaction Report
Form 4
Kerr Douglas
Chief Medical Officer
Transactions
- Award
Stock option (right to buy)
2025-07-16+65,110→ 65,110 totalExercise: $9.33Exp: 2035-07-15→ Common Stock (65,110 underlying)
Footnotes (1)
- [F1]This option was granted on July 16, 2025 (the "Grant Date"). The shares underlying the option are scheduled to vest over three years, with 50% of the shares underlying the grant vesting 18 months after the Grant Date and with the balance of the shares underlying the grant vesting in equal quarterly installments thereafter; provided that such option shall not be exercisable unless and until (i) the average closing price of the common stock on the Nasdaq Global Select Market over a 20 consecutive trading day period equals or exceeds $20.00 per share at any time during the three-year period following the Grant Date (the "Performance Period") or (ii) a Change in Control (as defined in the Issuer's Amended and Restated Executive Severance and Change in Control Benefits Plan) is consummated during the Performance Period pursuant to which a third party acquires the common stock for a price per share that the Board of Directors of the Issuer determines equals or exceeds $20.00 per share.
Documents
Issuer
Dyne Therapeutics, Inc.
CIK 0001818794
Entity typeother
Related Parties
1- filerCIK 0001814189
Filing Metadata
- Form type
- 4
- Filed
- Jul 17, 8:00 PM ET
- Accepted
- Jul 18, 5:20 PM ET
- Size
- 6.1 KB